Arrowhead CEO Pitches $4B REDEMPLO Opportunity, but Filings Show No Product Sales Yet

What happened

At the BofA Healthcare Conference, Arrowhead CEO Chris Anzalone promoted a $4B revenue opportunity for REDEMPLO and highlighted upcoming RNAi pipeline readouts. However, the latest SEC filings reveal that reported revenue remains dominated by collaboration accounting, with no disclosed product sales from REDEMPLO. The near-term catalyst is the Q3 2026 sHTG Phase 3 topline, which is pivotal for the expansion thesis. At ~$64, the stock trades near the top of fair value, with limited margin of safety given the binary nature of the catalyst and rising fixed costs from commercialization. DeepValue's WAIT rating underscores the need for concrete proof of launch traction and pipeline execution before adding.

Implication

Arrowhead's risk/reward is balanced but skews negative given the lack of disclosed product sales, high debt costs, and reliance on a single binary catalyst. An attractive entry point exists near $55, offering a better margin of safety. Monitor Q2 earnings for the first disclosure of REDEMPLO sales and management's commentary on sHTG timelines.

Thesis delta

The BofA presentation reinforces the existing bullish narrative but introduces no new data, leaving the investment thesis unchanged. The stock's valuation still depends entirely on successful commercialization and the sHTG Phase 3 readout, both of which remain unproven. The thesis shifts only if REDEMPLO net sales materialize or if the sHTG timeline slips.